METASTATIC COLORECTAL CANCER

This phase 2 trial tests whether adding an experimental drug called tovecimig to standard chemotherapy (FOLFIRI) can shrink tumors or slow cancer growth in people with metastatic colorectal cancer who have already tried one prior treatment. The study will enroll 25 participants a…

This early-phase trial tests whether matching drug combinations to a patient's tumor characteristics can better control metastatic colorectal cancer. Researchers will use blood draws, biopsies, and imaging to track how tumors resist treatment. The study enrolls 100 adults with me…

This early-phase trial tests a combination of three drugs—TAS-102, bevacizumab, and serplulimab—in 20 people with metastatic colorectal cancer who have already had surgery to remove tumors. The goal is to see if the combination is safe and can delay cancer progression. Participan…

This early-phase trial will test whether adding semaglutide (a GLP-1 drug used for diabetes and weight loss) to standard chemotherapy is safe and tolerable for people with metastatic pancreatic, colorectal, or liver cancer. About 30 participants will receive weekly semaglutide in…

This phase 3 trial tests whether a blood test that measures tumor DNA (ctDNA) can help doctors decide when to reduce or switch chemotherapy in people with metastatic colorectal cancer. About 408 participants will be randomly assigned to either standard treatment or a strategy whe…

This phase 2 trial tests whether adding the immune-boosting drug ivonescimab to standard chemotherapy (FOLFIRI) helps people with advanced colorectal cancer live longer without their cancer growing. It compares this new combination to the current standard of FOLFIRI plus bevacizu…

This early-stage trial tests a personalized cancer vaccine called ODI-2001 in 77 people with advanced colon or pancreatic cancer that has spread or cannot be removed. The vaccine is custom-made for each patient's tumor and is given along with a drug that boosts the immune system.…

This study tests whether giving immunotherapy before surgery can help people with a common type of colorectal cancer (MSS) that has spread to the liver. About 24 participants will receive the drug dupilumab before their liver surgery. The goal is to see if this approach is safe a…

This Phase 1 trial tests a new drug called HLX05-N, which is a biosimilar (a copy) of the cancer drug Erbitux, in 387 people with metastatic colorectal cancer. Participants will receive either HLX05-N or Erbitux (from the US or EU) along with standard chemotherapy. The study aims…

This phase 2 trial tests whether adding targeted radiation (SBRT) and an immunotherapy drug (sintilimab) to standard chemotherapy (TAS-102) and bevacizumab can help people with recurrent metastatic colorectal cancer live longer without their cancer growing. The study will enroll …

This study tests a drug called fruquintinib in 88 adults with advanced colon cancer that has not responded to standard chemotherapies. The goal is to see if adding supportive care to manage side effects can help patients live longer without their cancer growing. Participants will…

This phase 2 trial tests whether adding image-guided radioactive seed implants to standard cancer therapy can slow disease progression in patients with oligoprogressive metastatic lung or colorectal cancer. About 90 adults whose cancer has started to progress in a few spots while…

This study tests a minimally invasive procedure that uses heat (radiofrequency or microwave) to destroy abnormal growths in the abdominal wall, such as cancer spread, desmoid tumors, or endometriosis. It involves 30 people who cannot have surgery or choose not to. The goal is to …

This study tests a new platform called xDRIVE that combines drug sensitivity testing and AI to predict which treatments will work best for people with advanced colorectal cancer. The platform will not provide treatment itself but will give doctors a recommendation. The goal is to…

This study will follow 110 adults in Poland with metastatic colorectal cancer (cancer that has spread) who are taking fruquintinib after at least two prior treatments. Researchers will track how long patients live without their cancer getting worse and their overall survival, usi…